نتائج البحث

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

• Source: Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/

تفاصيل العنوان

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

• Source: A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

تفاصيل العنوان

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

• Authors : Pharmacyclics LLC.

• Source: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

تفاصيل العنوان

AS-1763 in Patients with Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

• Source: A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

تفاصيل العنوان

B-Cell Hematologic Malignancy Vaccination Registry (HMvax-Regist)

• Authors : Vince Lombardi Cancer Clinic

• Source: B-Cell Hematologic Malignancy Vaccination Registry

تفاصيل العنوان

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

• Authors : Eli Lilly and Company

• Source: A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)Cohen JB, Shah NN, Alencar

تفاصيل العنوان

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma (ARIADNE)

• Authors : BeiGene Switzerland GmbH

• Source: Zanubrutinib (Brukinsa®) in Patients With Waldenström's Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL) and Follicular

تفاصيل العنوان

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

• Authors : National Cancer Institute (NCI)

• Source: A Phase I Study of Pevonedistat (MLN4924, TAK924) in Combination With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

تفاصيل العنوان

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

• Authors : National Cancer Institute (NCI); Celgene; Joseph Tuscano, Principal Investigator

• Source: A Phase I/IB Pilot Study of CC-486 Combined with Lenalidomide and Obinutuzumab for Relapsed/Refractory Indolent B-Cell Lymphoma

تفاصيل العنوان

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

• Authors : The Leukemia and Lymphoma Society; Irene Ghobrial, MD, Principal Investigator

• Source: Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome

تفاصيل العنوان